We compared a case-series of ten patients who developed prolonged neuromuscular weakness after continuous, nondepolarizing, neuromuscular blockade with a group of controls without neuromuscular weakness to determine the economic impact of the neuromuscular weakness.
Frequency-matched case control trial.
Medical and surgical intensive care units of a 937-bed tertiary care, university-affiliated teaching hospital.
Ten patients developed prolonged neuromuscular weakness after continuous administration of nondepolarizing neuromuscular blockers.
Ten patients from a 1994 drug utilization database who did not develop motor weakness after paralysis were Identified to serve as controls.
The medical and accounting records of the patients were retrospectively reviewed.
Charge data were obtained from patient accounts.
Institutional ratios to convert charges to full costs and marginal costs were obtained from the Hospital Finance Department of Henry Ford Hospital.
The economic impact of the diagnosis and recovery of the motor weakness was estimated for the intensive care unit (ICU) and hospital stays and compared with those values for control patients. (...)
Mots-clés Pascal : Curarisation, Curarisant, Complication, Paralysie, Economie santé, Analyse coût, Toxicité, Chimiothérapie, Homme, Soin intensif, Système nerveux pathologie, Trouble moteur
Mots-clés Pascal anglais : Neuromuscular blocking, Neuromuscular blocking agent, Complication, Paralysis, Health economy, Cost analysis, Toxicity, Chemotherapy, Human, Intensive care, Nervous system diseases, Motor system disorder
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0003539
Code Inist : 002B02U01. Création : 21/05/1997.